3271F Low risk prostate cancer
Other
Also known as: low-risk prostate cancer staging, favorable-risk prostate cancer, T1-T2 Gleason 6 PSA <10
Performance measure for prostate cancer classified as low-risk disease. Quality metric documenting risk stratification for treatment planning and monitoring decisions.
Clinical Context
Quality measure for prostate cancer risk assessment, used to guide treatment decisions between active surveillance, radiation, or surgery based on disease characteristics.
RVU Breakdown
| Work RVU | 0.00 |
| Practice Expense RVU | 0.00 |
| Malpractice RVU | 0.00 |
| Total RVU | 0.00 |
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.